Fennec Pharmaceuticals Inc (FRX.TO) has shown modest weekly gains amidst recent financial updates and a strategic equity offering.
This week, Fennec Pharmaceuticals Inc (FRX.TO) experienced a slight increase in its stock price, closing at C$14.82, which is a 0.92% rise over the past week. The company recently announced significant financial results and business developments contributing to its performance.
Advertisement
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$541.09M
52W high
$17.64
52W low
$7.59
1W change
+0.92%
Beta
1.10
Analyst Price Targets
Based on analyst covering FRX · as of Sep 17, 2026
Wall Street analysts forecast FRX stock price to rise 506.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+506.4% Upside
Current Price
C$15.43
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
63.4%
Annualized
90-Day Vol
78.3%
Annualized
Trend (90d)
+19.2%
Annualized drift
90d Mean
C$16.53
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$15.79 | C$12.69 – C$19.65 |
| 60 trading days | C$16.15 | C$11.85 – C$22.01 |
| 90 trading days | C$16.53 | C$11.31 – C$24.14 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should pay attention to the strong sales growth and strategic initiatives highlighted in Fennec's recent announcements, along with the implications of their equity offering on future capital needs.
Fennec Pharmaceuticals Reports 50% Growth in Annual Revenue
The company achieved net product sales of $44.6 million in the past year, reflecting a significant increase and a positive trend in their operational performance.
Bull case
Fennec's record annual revenue and successful clinical strategies position the company strongly within the healthcare sector, likely attracting sustained investor interest.
Bear case
Despite the positive financial results, Fennec's ongoing negative profit margins and high beta may pose risks for investors seeking stability.
Recent Price Action
Fennec Pharmaceuticals Inc (FRX.TO) closed at C$14.82, showing no change on the day but a modest increase of 0.92% over the past week. Year-to-date, the stock has appreciated by 48.22%, indicating strong investor sentiment despite some fluctuations in monthly performance.
Company News and Developments
Advertisement
Fennec Pharmaceuticals recently reported its fourth-quarter and full-year 2025 financial results, highlighting a remarkable 50% year-over-year growth in net PEDMARK® product sales, reaching $44.6 million. Additionally, the company announced a successful oversubscribed equity offering aimed at raising approximately $42 million, expected to strengthen its financial position and support ongoing clinical studies. These developments underscore Fennec's strategic focus on expanding its market presence and enhancing its product offerings through clinical validation.
Technical Picture
From a technical perspective, Fennec Pharmaceuticals' stock is currently trading below its 50-day moving average of C$15.70, suggesting potential resistance at this level. However, it remains well above its 200-day moving average of C$12.33, indicating a longer-term bullish trend. The stock's 52-week range is C$7.59 to C$17.64, with current trading reflecting 72% of this range. The beta of 1.10 suggests that the stock may be slightly more volatile than the market, which could influence investor sentiment.
Insider Activity
There is no current insider activity reported for Fennec Pharmaceuticals, which may indicate stability in management and ownership structures at this time.
Price Action Summary
Fennec Pharmaceuticals Inc (FRX.TO) closed at C$14.82, reflecting a 0.00% change on the day. Investors may want to monitor upcoming developments as the company continues to execute its strategic initiatives.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
